Lupin (500257) Stock Overview
Operates as a pharmaceutical company in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
500257 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lupin Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,442.10 |
| 52 Week High | ₹2,530.00 |
| 52 Week Low | ₹1,838.65 |
| Beta | 0.18 |
| 1 Month Change | 7.73% |
| 3 Month Change | 5.07% |
| 1 Year Change | 26.48% |
| 3 Year Change | 161.23% |
| 5 Year Change | 106.72% |
| Change since IPO | 81,987.40% |
Recent News & Updates
Recent updates
Narrative Update • Jun 16
500257: US Drug Approvals And China Entry Will Support Steady Outlook
The analyst fair value estimate for Lupin has been nudged higher from ₹2,458.50 to roughly ₹2,466.51, with analysts pointing to refined assumptions around its long term profit margin profile and future P/E multiple as key drivers of the updated price target. What’s in the News for Lupin The U.S. FDA approved Lupin’s Ranluspec (ranibizumab hkdz) as an interchangeable biosimilar to Lucentis in both vial and pre filled syringe formats across approved strengths, expanding its ophthalmology offering in the United States.Narrative Update • Jun 02
500257: US Approvals And New Markets Will Support Steady Outlook
Analysts have lifted Lupin's price target from ₹2,426.53 to ₹2,458.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their refreshed models. What's in the News Received U.S. FDA approval for generic Sutab equivalent Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, with Lupin as exclusive first to file and eligible for 180 days of generic drug exclusivity; the product will be manufactured at the Nagpur facility in India (source: company announcement).Narrative Update • Apr 25
500257: US Approvals And New Partnerships Will Support Balanced Outlook
Analysts have inched up their fair value estimate for Lupin to about ₹2,426.53 from roughly ₹2,426.35, reflecting small tweaks to revenue growth and P/E assumptions, partly offset by slightly softer profit margin expectations. What's in the News Lupin has scheduled a board meeting on May 7, 2026 to consider audited standalone and consolidated results for the quarter and year ended March 31, 2026, and to recommend a dividend, if any (company filing).Narrative Update • Apr 11
500257: US Generics Approvals And Compliance Progress Will Support Balanced Outlook
Analysts have nudged their price target for Lupin slightly higher to about ₹2,426 from roughly ₹2,423, reflecting updated assumptions around revenue growth, profit margin and future P/E levels. What's in the News Lupin received U.S. FDA approval for Dapagliflozin and Metformin Hydrochloride Extended Release tablets across multiple strengths, including tentative approval for an additional 2.5 mg/1,000 mg strength, as a generic to Xigduo XR (Key Developments).Narrative Update • Mar 28
500257: US Approvals And Compliance Progress Will Shape Balanced Outlook
Lupin’s analyst price target has been adjusted slightly lower from ₹2,429.61 to ₹2,423.03, with analysts tying the change to updated assumptions on revenue growth, profit margins and future P/E expectations. What's in the News Received tentative US FDA approval for Pitolisant Tablets, 4.45 mg and 17.8 mg, deemed bioequivalent to Wakix, with manufacturing planned at the Nagpur facility in India (US FDA product-related approval).Narrative Update • Mar 14
500257: US Approvals And Compliance Progress Will Support Measured Forward Outlook
Analysts have nudged their Lupin price target slightly higher to about ₹2,430, citing small refinements to revenue growth, profit margin and future P/E assumptions in their models. What's in the News US FDA issued an Establishment Inspection Report with a Voluntary Action Indicated classification for Lupin's Goa facility following a November 2025 inspection, indicating the inspection has been closed out with identified issues not requiring major regulatory action (Regulatory Authority – Compliance).Narrative Update • Feb 26
500257: New US And EU Drug Launches Will Support Balanced Outlook
Analysts have raised their price target on Lupin by ₹120, reflecting updated assumptions that combine slightly lower revenue growth expectations with a modestly higher profit margin outlook and a small adjustment to the future P/E multiple. What's in the News Approval from the U.S. FDA for Brivaracetam Oral Solution 10 mg/mL, a generic version of Briviact Oral Solution, followed by its launch in the U.S. market, where the reference product has estimated annual sales of US$135 million (IQVIA MAT December 2025).Narrative Update • Feb 11
500257: New US Launches And TB Alliance Partnership Will Support Balanced Outlook
Analysts have nudged their price target on Lupin to ₹2,306. This reflects slightly adjusted assumptions around the discount rate, long term revenue growth, profit margin and future P/E they use in their models.Narrative Update • Jan 27
500257: Biosimilar Progress And New Licensing Deals Will Support Balanced Outlook
Analysts have nudged their price target on Lupin slightly higher, from ₹2,287.42 to ₹2,306.18, reflecting updated assumptions for revenue growth, profit margins, and future P/E. What's in the News Lupin signed an exclusive License, Supply and Distribution agreement with Gan & Lee Pharmaceuticals for Bofanglutide, a fortnightly GLP-1 receptor agonist for type 2 diabetes and weight management.Narrative Update • Jan 07
500257: Biosimilar Deals And US Regulatory Progress Will Support Balanced Outlook
Analysts have nudged their fair value estimate for Lupin slightly higher to ₹2,287.42 from ₹2,280.84, reflecting updated assumptions around long term revenue growth, profit margins, and a future P/E of 35.63x versus the prior 35.35x. What's in the News Lupin signed an exclusive license, supply and distribution agreement with Gan & Lee Pharmaceuticals for Bofanglutide, a fortnightly GLP-1 receptor agonist for type 2 diabetes and obesity, and received exclusive commercialization rights in India.Narrative Update • Dec 23
500257: Biosimilar And US Regulatory Progress Will Support Balanced Share Performance
Analysts have modestly maintained their conviction on Lupin with the analyst price target effectively unchanged at ₹2,280.84, reflecting stable assumptions on revenue growth, profitability and valuation multiples despite minor model refinements. What's in the News European regulator CHMP issued a positive opinion for Lupin's biosimilar ranibizumab Ranluspec for multiple retinal indications, moving the product closer to centralized EU approval and commercialization via Sandoz and Biogaran in select markets (CHMP, EMA).Narrative Update • Dec 09
500257: US FDA Approvals And Oncology Capacity Expansion Will Drive Shares Higher
Analysts have nudged their price target on Lupin slightly higher to approximately ₹2,281 from about ₹2,278, citing marginally stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Lupin signed an exclusive licensing deal with Valorum Biologics for its pegfilgrastim biosimilar Armlupeg in the U.S., retaining manufacturing while earning upfront and royalty payments on sales (client announcement).Narrative Update • Nov 25
500257: US FDA Inspections And Oncology Expansion Will Drive Shares Higher
Analysts have raised their price target for Lupin from ₹2,255.81 to ₹2,278.13, citing improved revenue growth expectations as outweighing a slight reduction in estimated profit margins. What's in the News The U.S. FDA completed a pre-approval inspection of Lupin's Nagpur oral solid dosage facility with zero 483 observations, confirming full compliance (Regulatory filing).Narrative Update • Nov 10
500257: Expansion In United States Operations Will Drive Long-Term Upside
Analysts have raised their price target for Lupin from ₹2,224.81 to ₹2,255.81. This reflects updated expectations around growth and margin assumptions.Narrative Update • Sep 05
Emerging Markets And Chronic Therapies Will Expand Global Horizons
With both consensus revenue growth forecasts and future P/E estimates for Lupin remaining steady, analysts have left their fair value price target unchanged at ₹2225. What's in the News Lupin launched multiple generic drugs in the US, including Bosentan Tablets for Oral Suspension (first-to-file status), Glucagon for Injection, Loteprednol Etabonate Ophthalmic Suspension, Prucalopride Tablets, Ipratropium Bromide Nasal Solution, and secured FDA approvals for Liraglutide Injection and Oxcarbazepine Extended-Release Tablets.
New Narrative • Nov 18
Innovative R&D And Product Expansion Fuel Robust Growth In Global Markets
Strong commercial execution and new product launches in key markets drive significant revenue growth, particularly in the U.S. and India.Shareholder Returns
| 500257 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.2% | 0.8% | 0.8% |
| 1Y | 26.5% | 11.6% | -1.2% |
Return vs Industry: 500257 exceeded the Indian Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: 500257 exceeded the Indian Market which returned -1.2% over the past year.
Price Volatility
| 500257 volatility | |
|---|---|
| 500257 Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: 500257 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 500257's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 26,021 | Vinita Gupta | www.lupin.com |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
Lupin Limited Fundamentals Summary
| 500257 fundamental statistics | |
|---|---|
| Market cap | ₹1.14t |
| Earnings (TTM) | ₹53.33b |
| Revenue (TTM) | ₹279.58b |
20.9x
P/E Ratio4.0x
P/S RatioIs 500257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500257 income statement (TTM) | |
|---|---|
| Revenue | ₹279.58b |
| Cost of Revenue | ₹79.65b |
| Gross Profit | ₹199.93b |
| Other Expenses | ₹146.60b |
| Earnings | ₹53.33b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 116.63 |
| Gross Margin | 71.51% |
| Net Profit Margin | 19.07% |
| Debt/Equity Ratio | 26.3% |
How did 500257 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield15%
Payout RatioDoes 500257 pay a reliable dividends?
See 500257 dividend history and benchmarks| Lupin dividend dates | |
|---|---|
| Ex Dividend Date | Jul 17 2026 |
| Dividend Pay Date | Sep 03 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 47 days |
Does 500257 pay a reliable dividends?
See 500257 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 11:42 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lupin Limited is covered by 60 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |